Thaumaturgical Analysis of Celldex (CLDX) Through March 31, 2015

November 21, 2014 – I think it’s safe to say that I misinterpreted the outcome here in this quarter, but I remain convinced that the cards told an accurate story.  I’m also of the belief that the company pre-released more data from the REACT trial because they feared that waiting another day would have them missing the p value on their primary endpoint (it clocked in at p= 0.048) and thereby creating less of a positive stir.

I’m not going to be buying stock here in Q4 simply because I believe management is still gravely concerned about other issues.  Q1 2015 is a good time to reconsider and possibly buy.